SLShan Liu

Shan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shan Liu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Bing Zhou

    University of South China

    1 shared publication
  • Fenfen Gui

    University of South China

    1 shared publication
  • Juan Tang

    Key Laboratory of Heart Failure Prevention & Treatment of Hengyang, Department of Cardiovascular Medicine, Clinical Medicine Research Center of Arteriosclerotic Disease of Hunan Province, Hengyang Medical School, The Second Affiliated Hospital, University of South China, Hengyang, China

    1 shared publication
  • Qi-Xia Tang

    Graduate Collabrative Training Base of The Second Affiliated Hospital, Hengyang, China

    1 shared publication
  • Rongping Xie

    Shaoyang Central Hospital

    1 shared publication
  • Xia Zhang

    University of South China

    1 shared publication

Latest Publications

  • Open Access

    cRGD Nanoparticles Loaded with Microbubbles for enhancing anti-Proliferation and anti-Angiogenesis

    by Xia Zhang, Fenfen Gui, Bing Zhou, Rongping Xie, Shan Liu

    Background The inhibition of angiogenesis leads to the degeneration of tumors; thus, anti-angiogenesis therapy is a strategy for the treatment of tumors. Accumulating documents has demonstrated effective anti-angiogenic strategies should simultaneously inhibit endothelium-dependent vessels (EDV) and tumor cell-mediated vasculogenic mimicry (VM). Although cRGD peptide enabling to bind with αvβ3 integrin can specifically inhibit both EDV and VM, however peptide-based drug delivery platforms have not obtained the expected therapeutic efficacy due to their rapid degradation and low tumor accumulation. Results Herein, we developed cRGD nanoparticles (cRGD Nano) loaded microbubbles (MB) to enhance their anti-EDV and anti-VM ability for endothelial cells and ovarian cancer cells due to the sonoporation effect from ultrasound (US). Heparin as backbone conjugated with cRGD to prepare cRGD-H conjugate and then loaded with biotin thereby following dialysis to fabricate cRGD Nano. Subsequently, the cRGD Nano were incorporated with MB via avidin-biotin linkage to fabricate cRGD Nano-MB. The enhanced anti-angiogenic effect can take profit of cRGD from cRGD Nano and sonoporation effect from US combined with MB. cRGD Nano has been characterized, and cRGD Nano-MB combined with US exhibited the best intracellular uptake ability than cRGD Nano and cRGD Nano-MB without US by flow cytometry and confocal laser scanning microscopy. Also, cRGD Nano-MB combined with US could efficiently discourage the tube formation of endothelial cells and cancer cells, and presented excellent significant anti-proliferation activity in vivo. Conclusions The combination of cRGD Nano-MB and US is expected to be a promising strategy for peptide drug delivery and enhancing anti-proliferation and anti-angiogenesis.